Anixa Biosciences, Inc.

ANIX · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders5.5%

Institutions14.2%

Public / Other

	You	Peer avg
Revenue Growth	–	+82.2%
ROE	-72.0%	-111.4%

Income Statement

	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31	2017-10-31	2015-10-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	$210000	–	$512500	–	$250000	$1.11M	$362500	$9.26M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$11.70M	-$13.83M	-$11.01M	-$13.88M	-$13.14M	-$9.98M	-$11.89M	-$14.29M	-$6.08M	-$944759
Operating income as a percentage of revenue.	–	–	-5243.3%	–	-2563.1%	–	-4756.0%	-1284.4%	-1676.0%	-10.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$101000	-$144000	-$119000	-$176000	-$173523	-$74008	-$171598	-$247059	-$7.02M	-$1.38M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$0.00	$-0.45	$-0.45	$0.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$0.00	–	–	–	–	–	–	–

Balance Sheet

	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31	2017-10-31	2015-10-31
Cash and highly liquid short-term investments the company can access almost immediately.	$1.24M	$1.27M	$915000	$12.36M	$29.13M	$6.42M	$3.49M	$3.06M	$3.34M	$4.37M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$16.08M	$21.59M	$25.52M	$30.41M	$36.26M	–	$6.29M	$6.45M	$8.81M	$9.34M
Everything the company owes — debt, unpaid bills, and other obligations.	$2.13M	$2.70M	$2.15M	$2.21M	$1.49M	–	–	–	$889493	$4.28M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$15.16M	$20.00M	$24.34M	$29.05M	$35.44M	–	$5.24M	$5.43M	$7.92M	$5.05M

Cash Flow Statement

	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31	2017-10-31	2015-10-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$7.17M	-$7.33M	-$6.21M	-$6.49M	-$4.94M	-$6.18M	-$4.74M	-$4.27M	-$3.80M	$1.36M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	–	–	$15791	$175457	$38404	$30188	$54776
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	–	–	-$6.19M	-$4.92M	-$4.31M	-$3.83M	$1.31M

Anixa Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement